Magnetic fluid hyperthermia: Advances, challenges, and opportunity

International Journal of Hyperthermia

Volumn 29, Issue 8, 2013, Pages 706-714

  Kozissnik, Bettina ^a   Bohorquez, Ana C ^a   Dobson, Jon ^a,b   Rinaldi, Carlos ^a  

^a J Crayton Pruitt Family Department of Biomedical Engineering   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Eddy current heating; Local energy delivery; Magnetic nanoparticles; Magnetically mediated energy delivery; Nanoscale thermal effects; Specific absorption rate; Systemic delivery

Indexed keywords

MAGNETIC NANOPARTICLE;

CANCER THERAPY; ELECTRIC CONDUCTIVITY; ELECTROMAGNETIC FIELD; ELECTROMAGNETIC RADIATION; ENERGY; HEATING; HUMAN; HYPERTHERMIA; HYPERTHERMIC THERAPY; MAGNETIC FLUID HYPERTHERMIA; REVIEW;

ANIMALS; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC PHENOMENA; NANOPARTICLES; NEOPLASMS;

EID: 84887982606     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2013.837200     Document Type: Review

References (99)

1. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2003; 36:167-81.
2. Pankhurst QA, Thanh NKT, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2009;42:224001.
3. Marincek B. Diagnostic improvement in MRI of gynecological neoplasms. J Belg Radiol 1996;79:13-17. (Pubitemid 26120952)
4. Reimer P, Balzer T. Ferucarbotran (Resovist): A new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: Properties, clinical development, and applications. Eur Radiol 2003;13:1266-76. (Pubitemid 36790627)
5. Auerbach M. Ferumoxytol as a new, safer, easier-to-administer intravenous iron: Yes or no? Am J Kidney Dis 2008;52:826-9.
6. Owen J, Pankhurst Q, Stride E. Magnetic targeting and ultrasound mediated drug delivery: Benefits, limitations and combination. Int J Hyperthermia 2012;28:362-73.
7. Sarwar A, Lee R, Depireux DA, Shapiro B. Magnetic injection of nanoparticles into rat inner ears at a human head working distance. IEEE Trans Magn 2013;49:440-52.
8. Mannix RJ, Kumar S, Cassiola F, Montoya-Zavala M, Feinstein E, Prentiss M, Ingber DE. Nanomagnetic actuation of receptormediated signal transduction. Nat Nanotechnol 2008;3:36-40.
9. Dobson J. Remote control of cellular behaviour with magnetic nanoparticles. Nat Nanotechnol 2008;3:139-43. (Pubitemid 351355134)
10. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. Magnetofection: Enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J Liposome Res 2003;13:29-32. (Pubitemid 36373341)
11. Schillinger U, Rutz M, Fischer C, Jahnke AJ, Walsch F, Ferizi M, et al. Novel immunostimulatory therapy by adjuvant magnetofection prolongs relapse-free survival of fibrosarcoma bearing cats: A veterinary clinical study. Hum Gene Ther 2010;21:1210-11.
12. Otte J. Hyperthermia in cancer therapy. Eur J Pediatr 1988;147: 560-9.
13. van der Zee J. Heating the patient: A promising approach? Ann Oncol 2002;13:1173-84.
14. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487-97. (Pubitemid 34863670)
15. Johannsen M, Gneveckow U, Taymoorian K, Thiesen B, Waldofner N, Scholz R, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. Int J Hyperthermia 2007;23:315-23. (Pubitemid 46860598)
16. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011;103:317-24.
17. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487-97. (Pubitemid 34863670)
18. Chichel A, Skowronek J, Kubaszewska M, Kanikowski M. Hyperthermia- Description of a method and a review of clinical applications. Rep Pract Oncol Radiother 2007;12:267-75. (Pubitemid 350097246)
19. Gilchrist RK, Medal R, Shorey WD, Hanselman RC, Parrott JC, Taylor CB. Selective inductive heating of lymph nodes. Ann Surg 1957;146:596-606.
20. Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater 2002;252:370-74.
21. Liu TY, Hu SH, Liu DM, Chen SY, Chen IW. Biomedical nanoparticle carriers with combined thermal and magnetic responses. Nano Today 2009;4:52-65.
22. Gonzales-Weimuller M, Zeisberger M, Krishnan KM. Size-dependant heating rates of iron oxide nanoparticles for magnetic fluid hyperthermia. J Magn Magn Mater 2009;321:1947-50.
23. Suto M, Hirota Y, Mamiya H, Fujita A, Kasuya R, Tohji K, Jeyadevan B. Heat dissipation mechanism of magnetite nanoparticles in magnetic fluid hyperthermia. J Magn Magn Mater 2009; 321:1493-6.
24. Lee JH, Jang JT, Choi JS, Moon SH, Noh SH, Kim JW, et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol 2011;6:418-22.
25. Lartigue L, Hugounenq P, Alloyeau D, Clarke SP, Levy M, Bacri JC, et al. Cooperative organization in iron oxide multi-core nanoparticles potentiates their efficiency as heating mediators and MRI contrast agents. ACS Nano 2012;6:10935-49.
26. Krishnan KM. Biomedical nanomagnetics: A spin through possibilities in imaging, diagnostics, and therapy. IEEE Trans Magn 2010;46:2523-58.
27. Natividad E, Castro M, Mediano A. Adiabatic magnetothermia makes possible the study of the temperature dependence of the heat dissipated by magnetic nanoparticles under alternating magnetic fields. Appl Phys Lett 2011;98:243119.
28. Huang S, Wang SY, Gupta A, Borca-Tasciuc DA, Salon SJ. On the measurement technique for specific absorption rate of nanoparticles in an alternating electromagnetic field. Meas Sci Technol 2012;23: 035701.
29. Frimpong RA, Hilt JZ. Magnetic nanoparticles in biomedicine: Synthesis, functionalization and applications. Nanomedicine 2010; 5:1401-14.
30. Ho D, Sun X, Sun S. Monodisperse magnetic nanoparticles for theranostic applications. Account Chem Res 2011;44:875-82.
31. Kievit FM, Zhang M. Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Account Chem Res 2011;44:853-62.
32. Ling D, Hyeon T. Chemical design of biocompatible iron oxide nanoparticles for medical applications. Small 2012;9: 1450-66.
33. Kallumadil M, Tada M, Nakagawa T, Abe M, Southern P, Pankhurst QA. Suitability of commercial colloids for magnetic hyperthermia. J Magn Magn Mater 2009;321:1509-13.
34. Kallumadil M, Tada M, Nakagawa T, Abe M, Southern P, Pankhurst QA. Corrigendum to: "Suitability of commercial colloids for magnetic hyperthermia" (vol 321, pg 1509, 2009). J Magn Magn Mater 2009;321:3650-1.
35. Guardia P, Di Corato R, Lartigue L, Wilhelm C, Espinosa A, Garcia-Hernandez M, et al. Water-soluble iron oxide nanocubes with high values of specific absorption rate for cancer cell hyperthermia treatment. ACS Nano 2012;6:3080-91.
36. Atkinson WJ, Brezovich IA, Chakraborty DP. Usable frequencies in hyperthermia with thermal seeds. IEEE Trans Biomed Eng 1984; 31:70-5. (Pubitemid 14150050)
37. ICNIRP. Guidelines for limiting exposure to time-varying electric, magnetic and electromagnetic fields (up to 300 GHz). Available from http://www.icnirp.de/documents/emfgdl.pdf (accessed 1 May 2013).
38. FDA. A primer on medical device interactions with magnetic resonance imaging systems. Available from http://www. fda.gov/MedicalDevices/ DeviceRegulationandGuidance/Guidance Documents/ucm107721.htm (accessed 1 May 2013).
39. Oleson JR. A review of magnetic induction methods for hyperthermia treatment of cancer. IEEE Trans Biomed Eng 1984;31:91-7. (Pubitemid 14150052)
40. Stuchly MA. Health effects of exposure to electromagnetic fields. Aspen, CO: Aerospace Applications Conference; 1995. pp 351-68.
41. Carrara N. An internet resource for the calculation of the dielectric properties of body tissues in the frequency range of 10 Hz-100 GHz. Available from http://niremf.ifac.cnr.it/tissprop/(accessed 28 May 2013).
42. Bagaria HG, Johnson DT. Transient solution to the bioheat equation and optimization for magnetic fluid hyperthermia treatment. Int J Hyperthermia 2005;21:57-75. (Pubitemid 40124623)
43. Giordano MA, Gutierrez G, Rinaldi C. Fundamental solutions to the bioheat equation and their application to magnetic fluid hyperthermia. Int J Hyperthermia 2010;26:475-84.
44. Diller K, Valvano J, Pearce J. Bioheat transfer. In: Kreith F, Timmerhaus K, Lior N, Shaw H, Shah RK, Bell KJ, editors. The CRC Handbook of Thermal Engineering. Boca Raton, FL: CRC Press; 2000. pp 114-87.
45. Giustini AJ, Ivkov R, Hoopes PJ. Magnetic nanoparticle biodistribution following intratumoral administration. Nanotechnology 2011;22:345101.
46. Jordan A, Scholz R, Wust P, Fahling H, Krause J, Wlodarczyk W, et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia 1997;13:587-605. (Pubitemid 27496845)
47. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011;103:317-24.
48. van Landeghem FK, Maier-Hauff K, Jordan A, Hoffmann KT, Gneveckow U, Scholz R, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 2009;30:52-7.
49. Johannsen M, Gneueckow U, Thiesen B, Taymoorian K, Cho CH, Waldofner N, et al. Thermotherapy of prostate cancer using magnetic nanoparticles: Feasibility, imaging, and three-dimensional temperature distribution. Eur Urol 2007;52:1653-62. (Pubitemid 350052385)
50. Johannsen M, Jordan A, Scholz R, Koch M, Lein M, Deger S, et al. Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. J Endourol 2004;18:495-500. (Pubitemid 38879152)
51. Jordan A, Scholz R, Maier-Hauff K, van Landeghem FKH, Waldoefner N, Teichgraeber U, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2006;78:7-14. (Pubitemid 43786652)
52. Moroz P, Jones SK, Winter J, Gray BN. Targeting liver tumors with hyperthermia: Ferromagnetic embolization in a rabbit liver tumor model. J Surg Oncol 2001;78:22-9.
53. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Ipe BI, et al. Renal clearance of quantum dots. Nat Biotechnol 2007;25: 1165-70. (Pubitemid 47538116)
54. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65:271-84. (Pubitemid 30122932)
55. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207.
56. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136-51.
57. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012;164: 108-14.
58. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175-87.
59. Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. J Control Release 2012;164:138-44.
60. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release 2012;164:265-75.
61. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 2013;65:71-9.
62. WC Miles, Goff JD, Huffstetler PP, Reinholz CM, Pothayee N, Caba BL, et al. Synthesis and colloidal properties of polyethermagnetite complexes in water and phosphate buffered saline. Langmuir 2009;25:803-13.
63. Creixell M, Herrera AP, Latorre-Esteves M, Ayala V, Torres-Lugo M, Rinaldi C. The effect of grafting method on the colloidal stability and in vitro cytotoxicity of carboxymethyl dextran coated magnetic nanoparticles. J Mater Chem 2010;20:8539.
64. Konda SD, Aref M, Wang S, Brechbiel M, Wiener EC. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA 2001;12:104-113. (Pubitemid 32510128)
65. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26:3995-4021. (Pubitemid 40044762)
66. Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chem 2005;16:1181-8. (Pubitemid 41368119)
67. Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res Part A 2006;78A:550-7. (Pubitemid 44253539)
68. Yoo M-K, Park I-K, Lim H-T, Lee S-J, Jiang H-L, Kim Y-K, et al. Folate-PEG-superparamagnetic iron oxide nanoparticles for lung cancer imaging. Acta Biomater 2012;8:3005-13.
69. Mahajan S, Koul V, Choudhary V, Shishodia G, Bharti AC. Preparation and in vitroevaluation of folate-receptor-targeted SPION-polymer micelle hybrids for MRI contrast enhancement in cancer imaging. Nanotechnology 2012;24:015603.
70. Ahrens ET, Feili-Hariri M, Xu H, Genove G, Morel PA. Receptormediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med 2003;49:1006-13. (Pubitemid 36627278)
71. Grüttner C, Müller K, Teller J, Westphal F, Foreman A, Ivkov R. Synthesis and antibody conjugation of magnetic nanoparticles with improved specific power absorption rates for alternating magnetic field cancer therapy. J Magn Magn Mater 2007;311:181-6. (Pubitemid 46401005)
72. Xiong F, Zhu Z.-Y, Xiong C, Hua X-Q, Shan X-H, Zhang Y, Gu N. Preparation, characterization of 2-deoxy-D-glucose functionalized dimercaptosuccinic acid-coated maghemite nanoparticles for targeting tumor cells. Pharm Res 2011;29:1087-97.
73. Le B, Shinkai M, Kitade T, Honda H, Yoshida J, Wakabayashi T, Kobayashi T. Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J Chem Eng Jap 2001;34:66-72. (Pubitemid 32682967)
74. Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang X, et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2008;5:235-43.
75. Creixell M, Bohórquez AC, Torres-Lugo M, Rinaldi C. EGFRtargeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano 2011;5:7124-9.
76. Creixell M, Herrera AP, Ayala V, Latorre-Esteves M, Pérez-Torres M, Torres-Lugo M, Rinaldi C. Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. J Magn Magn Mater 2010; 322:2244-50.
77. Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chem Med Chem 2008;3:1311-15.
78. Yu MK, Kim D, Lee I-H, So J-S, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 2011;7:2241-9.
79. Bamrungsap S, Shukoor MI, Chen T, Sefah K, Tan W. Detection of lysozyme magnetic relaxation switches based on aptamer-functionalized superparamagnetic nanoparticles. Anal Chem 2011;83:7795-9.
80. Bamrungsap S, Chen T, Shukoor MI, Chen Z, Sefah K, Chen Y, Tan W. Pattern recognition of cancer cells using aptamerconjugated magnetic nanoparticles. ACS Nano 2012;6:3974-81.
81. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomedicine 2004;17: 484-99. (Pubitemid 39549426)
82. Yang L, Mao H, Cao ZH, Wang YA, Peng XH, Wang XX, et al. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology 2009;136: 1514-25.
83. Hadjipanayis CG, Machaidze R, Kaluzova M, Wang LY, Schuette AJ, Chen HW, et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convectionenhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010;70:6303-12.
84. Chen TJ, Cheng TH, Chen CY, Hsu SCN, Cheng TL, Liu GC, Wang YM. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009;14:253-60.
85. Ivkov R, DeNardo SJ, Daum W, Foreman AR, Goldstein RC, Nemkov VS, DeNardo GL. Application of high amplitude alternating magnetic fields for heat induction of nanoparticles localized in cancer. Clin Cancer Res 2005;11:S7093-103.
86. Gordon RT, Hines JR, Gordon D. Intracellular hyperthermia a biophysical approach to cancer treatment via intracellular temperature and biophysical alterations. Med Hypotheses 1979;5:83-102. (Pubitemid 9216973)
87. Rabin Y. Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int J Hyperthermia 2002;18: 194-202. (Pubitemid 34618578)
88. Keblinski P, Cahill DG, Bodapati A, Sullivan CR, Taton TA. Limits of localized heating by electromagnetically excited nanoparticles. J Applied Phys 2006;100:054305.
89. Huang H, Delikanli S, Zeng H, Ferkey DM, Pralle A. Remote control of ion channels and neurons through magnetic-field heating of nanoparticles. Nat Nanotechnol 2010;5:602-6.
90. Polo-Corrales L, Rinaldi C. Monitoring iron oxide nanoparticle surface temperature in an alternating magnetic field using thermoresponsive fluorescent polymers. J Applied Phys 2012;111: 07B334.
91. Uchiyama S, Matsumura Y, de Silva AP, Iwai K. Fluorescent molecular thermometers based on polymers showing temperatureinduced phase transitions and labeled with polarity-responsive benzofurazans. Anal Chem 2003;75:5926-35. (Pubitemid 37356475)
92. Amstad E, Kohlbrecher J, Müller E, Schweizer T, Textor M, Reimhult E. Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett 2011;11:1664-70.
93. Rodriguez-Luccioni HL, Latorre-Esteves M, Mendez-Vega J, Soto O, Rodriguez AR, Rinaldi C, Torres-Lugo M. Enhanced reduction in cell viability by hyperthermia induced by magnetic nanoparticles. Int J Nanomedicine 2011;6:373-80.
94. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 2009;25:3-20.
95. Lee JS, Rodriguez-Luccioni HL, Méndez J, Sood AK, Lpez-Berestein G, Rinaldi C, Torres-Lugo M. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol 2011; 11:4153-7.
96. Alvarez-Berrios MP, Castillo A, Mendez J, Soto O, Rinaldi C, Torres-Lugo M. Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity. Int J Nanomedicine 2013;8:1003-13.
97. Lepock JR. Involvement of membranes in cellular responses to hyperthermia. Radiat Res 1982;92:433-8. (Pubitemid 13221296)
98. Domenech M, Marrero-Berrios I, Torres-Lugo M, Rinaldi C. Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields. ACS Nano 2013;7: 5091-101.
99. Kepp O, Galluzzi L, Lipinski M, Yuan JY, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011;10:221-37.